Search 

Private equity firm

The United Nations called for the One Heath approach to combating pandemic threats at the 3 vectors of transmission: animals to people, people to people, and environment to people -- and vice versa.

Aequor is the only company with products that control antimicrobial-resistant (AMR) pathogens at all 3 vectors of transmission.

Twenty-five of our small molecules remove biofilm in minutes, prevent biofilm formation for days, kill AMR and multi-drug-resistant (MDR) pathogens alone and in combination with existing biocides at sub-MIC levels -- reducing the need for harmful, toxic biocides. These 25 are EPA approved and available in ton quantities. They are used in our proprietary products for environmental sanitation: surface cleaners, water treatments and industrial process enhancers (boost algae and yeast biomass by up to 40% for use in biofuels and bio-based co-products (food, feed, nutraceuticals, chemicals, plastics, materials, etc.).

Our new drug candidates are in pre-clinical Hit-to-Leas stage. They kill the latest clinical strains sent to Aequor by the NIH and CDC. The NIH awarded Aequor free pre-IND trials to develop up to 4 of them and the DOD offered the same to develop 5 of them. They are derived from a new genus and several new species of marine microbes that produce “green,” non-toxic chemicals that target Gram-negative and Gram-positive bacteria and fungi.

Our products uniquely kill bacteria and fungi at all stages of growth -- including biofilm. Biofilm is the first resistance response of microorganisms to protect themselves against environmental stresses and is associated with most infections and diseases. Removal of biofilm by surface scraping, UV, heat, biocides and antibiotics, etc. signal to the underlying microorganisms when and how fast to build a thicker biofilm shield.

The U.S. Centers for Disease Control (CDC) associate biofilm with 90% of hospital-acquired infections, such as those caused by contamination on indwelling medical devices, ventilators, and water and air systems. The CDC recently reported that 20% of U.S. COVID deaths were due to these secondary infections. Additional life-threatening infections are increasingly traced to biofilm in air and water systems in institutional and commercial buildings and homes. For example, Legionnaire’s Disease, which claimed 17 lives, was traced to biofilm in a hotel’s air conditioners that became aerosolized and inhaled. It is no coincidence that every pathogen on the CDC and WHO lists of urgent threats, pandemic threats, and bioterrorist threats is a biofilm-former. Every drug-resistant “Superbug” strain is a biofilm-former and is considered incurable. Additionally, several microbial species are captures in the same biofilm, increasing the incidence of horizontal gene transfer (Li et al., 2001; Angles et al., 1993; Dunny et al., 1995) and spawning the emergence of new antimicrobial-resistant (AMR) strains.

There are few remedies for biofilm. Physical removal (sterilization, scraping, UV) works for a short-term (e.g., biofilm was recorded on a titanium plate within 30 seconds of sterilization). Biocides (antiseptics, disinfectants, antimicrobials, and antibiotics) are designed to kill free-floating (planktonic), actively growing microorganisms, and the dose of needed to disrupt a biofilm is approximately 1000x the concentrations that are effective against planktonic bacteria (Raffa et al., 2003), which is a dose that is lethal to humans. The overuse of biocides and antibiotics has contributed to the emergence of the AMR Superbugs – and left a cumulative and persistent environmental footprint. Natural antimicrobials, such as silver and other metals, are expensive and eventually trigger the formation of thicker biofilm, resulting in the loss of efficacy over time.

If you combat biofilm at all vectors of transmission, you control AMR pandemic threats.

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.

Biotech

Manufacturing company

We bring foundational science and commercial viability together for social and market impact.

We provide a human innovation ecosystem offering commercially focused support for inventors.

DEEP TECH FUNDING REINVENTED WITH SCIENCE, FOR SCIENCE

6 practice areas: AI, Robotics, Life Science, Quantum Computing, Energy, Secure Platforms & Networks

Pharmalectin is working on the end-to-end solution for COVID-19 mild to severe cases and treatment for organ damage caused by the virus. The company has developed a novel method designed to reduce the viral load and modulate the immune system using a galectin inhibitor.

Academic study on a small number of patients with the first drug candidate had positive results. The viral load was reduced to zero in all mild/moderate patient after a few days. The drug is not toxic and had no adverse effects. It can prevent spread of infection in 24 hours. It is complementary to vaccination and can prevent infection from close contact. Next step is stage III trials for a bigger group of patients.

We are looking for investors to fund our next phase.

Investor

China医药创新促进会（原名“China医药工业科研开发促进会”,简称“China药促会”）,英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA）,成立于1988年,是经国家民政部登记注册的非营利性全国性4A级社会组织。
China药促会秉承“创新、产业化、国际化”的宗旨,以临床需求为导向,长期致力于“产学研用资”紧密结合,促进医药行业创新发展,已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台,目前有会员单位144家。China药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会,形成了以创新为核心,以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架,并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。